Cargando…

Clofazimine for Treatment of Mycobacterium abscessus Infections in Children

BACKGROUND: Mycobacterium abscessus infections are increasingly common and can be challenging to treat due to antimicrobial resistance. Clofazimine (CFZ), which is commonly used for treatment of leprosy, comes as a 50 mg capsule that must be swallowed whole. It has excellent in vitro activity agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Adler-Shohet, Felice C, Singh, Jasjit, Nieves, Delma, Ashouri, Negar, Tran, M Tuan, Flores, Cathy, Arrieta, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631425/
http://dx.doi.org/10.1093/ofid/ofx163.1804
_version_ 1783269467831140352
author Adler-Shohet, Felice C
Singh, Jasjit
Nieves, Delma
Ashouri, Negar
Tran, M Tuan
Flores, Cathy
Arrieta, Antonio
author_facet Adler-Shohet, Felice C
Singh, Jasjit
Nieves, Delma
Ashouri, Negar
Tran, M Tuan
Flores, Cathy
Arrieta, Antonio
author_sort Adler-Shohet, Felice C
collection PubMed
description BACKGROUND: Mycobacterium abscessus infections are increasingly common and can be challenging to treat due to antimicrobial resistance. Clofazimine (CFZ), which is commonly used for treatment of leprosy, comes as a 50 mg capsule that must be swallowed whole. It has excellent in vitro activity against M. abscessus but there are limited reports of its use, particularly in children. During a healthcare associated outbreak of M. abscessus odontogenic infections, 27 children were treated with a CFZ containing regimen for several months. METHODS: Data was collected on all children who received CFZ for a proven or probable M. abscessus odontogenic infection via a Food and Drug Administration Investigational New Drug Application. Demographic, diagnostic and therapeutic information was evaluated, as were laboratory results, adverse events and clinical outcomes. RESULTS: Of 27 children who received CFZ, 13 were male, 22 were Hispanic and mean age at initial dosing was 5.8 years (range 3.0 – 9.4 years). Patients also received azithromycin, amikacin and either imipenem or cefoxitin, though the β-lactam was stopped an average of 31 days after CFZ started. All 27 children had osteomyelitis of the jaw and received aggressive surgical debridement; 10 had a positive stain for acid-fast bacilli (AFB) and 14 had a positive AFB culture (13 M. abscessus, 1 M. chelonae). Lung nodules were present in 16 children and granulomatous lymphadenitis requiring surgery in 10. Patients received a mean of 105.6 total days of CFZ therapy (range 84–164 days) with a mean weekly dose of 7.6 mg/kg and with dosing occurring a mean of 3 days a week. Every child was able to swallow the CFZ capsule. Minor skin discoloration was noted in 6 children, dry skin in 17, and gastrointestinal symptoms in 11. No child had a clinically significant change in corrected QT interval. All children showed evidence of jaw healing and resolution of lymphadenitis at the end of therapy, and 14 had resolved or improving lung nodules. CONCLUSION: This is the largest reported case series of children receiving clofazimine for reasons other than leprosy. It is also the largest report of clofazimine use for extra pulmonary M. abscessus infections. Clofazimine appears to be safe in children and may be an effective part of a surgical and multi-drug regimen for M. abscessus infections. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631425
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56314252017-11-07 Clofazimine for Treatment of Mycobacterium abscessus Infections in Children Adler-Shohet, Felice C Singh, Jasjit Nieves, Delma Ashouri, Negar Tran, M Tuan Flores, Cathy Arrieta, Antonio Open Forum Infect Dis Abstracts BACKGROUND: Mycobacterium abscessus infections are increasingly common and can be challenging to treat due to antimicrobial resistance. Clofazimine (CFZ), which is commonly used for treatment of leprosy, comes as a 50 mg capsule that must be swallowed whole. It has excellent in vitro activity against M. abscessus but there are limited reports of its use, particularly in children. During a healthcare associated outbreak of M. abscessus odontogenic infections, 27 children were treated with a CFZ containing regimen for several months. METHODS: Data was collected on all children who received CFZ for a proven or probable M. abscessus odontogenic infection via a Food and Drug Administration Investigational New Drug Application. Demographic, diagnostic and therapeutic information was evaluated, as were laboratory results, adverse events and clinical outcomes. RESULTS: Of 27 children who received CFZ, 13 were male, 22 were Hispanic and mean age at initial dosing was 5.8 years (range 3.0 – 9.4 years). Patients also received azithromycin, amikacin and either imipenem or cefoxitin, though the β-lactam was stopped an average of 31 days after CFZ started. All 27 children had osteomyelitis of the jaw and received aggressive surgical debridement; 10 had a positive stain for acid-fast bacilli (AFB) and 14 had a positive AFB culture (13 M. abscessus, 1 M. chelonae). Lung nodules were present in 16 children and granulomatous lymphadenitis requiring surgery in 10. Patients received a mean of 105.6 total days of CFZ therapy (range 84–164 days) with a mean weekly dose of 7.6 mg/kg and with dosing occurring a mean of 3 days a week. Every child was able to swallow the CFZ capsule. Minor skin discoloration was noted in 6 children, dry skin in 17, and gastrointestinal symptoms in 11. No child had a clinically significant change in corrected QT interval. All children showed evidence of jaw healing and resolution of lymphadenitis at the end of therapy, and 14 had resolved or improving lung nodules. CONCLUSION: This is the largest reported case series of children receiving clofazimine for reasons other than leprosy. It is also the largest report of clofazimine use for extra pulmonary M. abscessus infections. Clofazimine appears to be safe in children and may be an effective part of a surgical and multi-drug regimen for M. abscessus infections. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631425/ http://dx.doi.org/10.1093/ofid/ofx163.1804 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Adler-Shohet, Felice C
Singh, Jasjit
Nieves, Delma
Ashouri, Negar
Tran, M Tuan
Flores, Cathy
Arrieta, Antonio
Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title_full Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title_fullStr Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title_full_unstemmed Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title_short Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
title_sort clofazimine for treatment of mycobacterium abscessus infections in children
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631425/
http://dx.doi.org/10.1093/ofid/ofx163.1804
work_keys_str_mv AT adlershohetfelicec clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT singhjasjit clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT nievesdelma clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT ashourinegar clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT tranmtuan clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT florescathy clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren
AT arrietaantonio clofaziminefortreatmentofmycobacteriumabscessusinfectionsinchildren